Bosutinib is a Src / Abl dual tyrosine kinase inhibitor approved for the treatment of newly diagnosed chronic phase (CP) chronic myelogenous leukemia (CML), or resistant or intolerant to previous treatments CML. The study compared data from first-line besutinib and imatinib treatments at ≥24 months of follow-up. BFORE is an ongoing, open-label phase III clinical study with a total of 536 patients enrolled and randomly assigned to receive bursatinib (n = 268) or imatinib (n = 268) in a 1: 1 ratio treatment.
At a follow-up of 12 months, compared with the imatinib group, the bosutinib group showed higher molecular remission (MR) and complete cytogenetic remission (CCyR). Sareng bédana ieu teras teras-terasan saatos 24 bulan. Dina 24 bulan tina tindak lanjut, dua kelompok nunjukkeun bédana remisi molekul utama (MMR), tapi bédana antara MR4 sareng MR4.5 henteu signifikan. Dibandingkeun sareng grup imatinib, waktos dugi ka MR sareng CCyR langkung pondok dina grup bosutinib. Genep pasién dina grup bosutinib sareng tujuh pasién dina grup imatinib dirobih kana fase gancangan / gancang. Dina 24 bulan tina tindak lanjut, dibandingkeun sareng grup imatinib, grup bosutinib nunjukkeun remisi molekul utama anu langkung luhur (MMR). Studi ngadukung panggunaan bosutinib dina lini pangobatan penderita CP CML.
